Boots and Upjohn trade -- an NSAID for E-Mycin
Executive Summary
Boots announced it has revised an existing licensing agreement to give Upjohn exclusive U.S. marketing rights to the nonsteroidal anti-inflammatory flurbiprofen (Upjohn's tradename Ansaid). The exclusive rights exclude topical ophthalmic uses. In exchange, Boots receives U.S. marketing rights to Upjohn's E-Mycin (erythromycin) and "other financial adjustments".